Feasibility of a Novel Process-based Treatment for Patients With Psychosis

Schizophrenia Clinical Trial

— PROBAS  

Official title:

The PROBAS-Study: Developing a Process-based and Modular Group Therapy for Acute Psychiatric Patients With Psychotic Symptoms: a Single-arm Feasibility Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04874974
• Other study ID #: 21-0025
• Status: Completed
• Phase: N/A
• Start date: May 10, 2021
• Est. completion date: September 23, 2023

Study information

• Verified date: October 2023
• Source: Max-Planck-Institute of Psychiatry
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this single-arm feasibility study is to develop and pilot test a novel process-based and modular group therapy approach for patients with acute psychotic symptoms in an inpatient setting.

Description:

Due to the enormous economic and social costs of psychotic-spectrum disorders, increasing the effectiveness of treatment options has become an important subject for psychiatric research. Latest findings in the field of psychotherapy for psychosis show some promising results for so-called Process-based Therapies (PBT) such as the Metacognitive Training (MCT) and Acceptance and Commitment Therapy (ACT) (Barnicot et al., 2020). Instead of trying to change the content of psychotic symptoms such as hallucinations and delusions, PBT directly address cognitive processes, which have been found to maintain the disorder's symptomatology (Hayes et al., 2020). While MCT focusses on changing patients' cognitive biases by inducing metacognition (Moritz & Woodward, 2007), ACT works with psychological processes such as mindfulness, willingness and cognitive distancing (Gaudiano & Herbert, 2006). There is a growing study base for PBT in a psychotic outpatient setting, research in non-ambulatory settings though is rare (Barnicot et al., 2020). Therefore, the aim of the current study is to develop and test the feasibility and safety of a new process-based group therapy program for acute psychotic patients. The five-week treatment approach will consist of three different modules combining interventions from both MCT and ACT (Module I: Psychoeducation, Module II: Metacognition, Module III: Cognitive Defusion). First preliminary effectiveness and process measures (PANSS, BPRS, WHO-DAS, CGI, BCIS and CFQ) will also be included in order to inform the design of future research. Thus, the study will give valuables insights in the feasibility and effectiveness of an innovative psychotherapy approach and breaks new ground in the field of psychotherapy research for psychosis.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 37
• Est. completion date: September 23, 2023
• Est. primary completion date: March 10, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• Main diagnosis of a mental disorder with psychotic symptoms according to ICD-10 criteria currently experiencing delusions and hallucinations (F20, F21, F22, F23, F24, F25, F28, F29, F30.2, F31.2, F31.5, F32.3, F33.3) indicated by diagnostic assessment of attending MD

• Age between 18 and 70 years

• Informed consent to the study procedures and assessments (in written form)

Exclusion Criteria:

• Severe neurological or internal concomitant diseases

• IQ < 80; severe learning disability, brain damage or pervasive developmental disorder

• Missing eligibility for psychotherapy because of missing language skills/hostile or uncooperative behaviour.

No further constraints will be imposed in order to collect data in a representative clinical sample.

Related Conditions & MeSH terms

• Bipolar Disorder
• Brief Psychotic Disorder
• Delusional Disorder
• Depression
• Depressive Disorder
• Depressive Disorder, Major
• Disease
• Mania
• Mental Disorders
• Psychotic Disorders
• Schizoaffective Disorder
• Schizophrenia
• Schizophrenia, Paranoid
• Schizotypal Disorder

Intervention

Behavioral:
• Metacognitive and Defusion Training
Module I will give a brief introduction into the rational of the therapy and explain the terms cognitive biases and relational responding and their role in the development of psychological problems (psychosis) in a simple language and with the help of examples and small exercises. The principle of metacognition and cognitive defusion in psychotherapy will be made clear. An outlook on the procedures and the goals of the group therapy will be given. Module II will include interventions adapted from the MCT manual (Moritz et al., 2017) and Module III with consist of defusion strategies taken from the ACT group manual (Dambacher et al., 2020) and existing studies on ACT and psychosis (Bach et al., 2013; Gaudiano & Herbert, 2006).

Locations

Country	Name	City	State
Germany	Max Planck Institute of Psychiatry	Munich	Bavaria

Sponsors (1)

Lead Sponsor	Collaborator
Max-Planck-Institute of Psychiatry

Country where clinical trial is conducted

Germany, 

References & Publications (4)

Barnicot K, Michael C, Trione E, Lang S, Saunders T, Sharp M, Crawford MJ. Psychological interventions for acute psychiatric inpatients with schizophrenia-spectrum disorders: A systematic review and meta-analysis. Clin Psychol Rev. 2020 Dec;82:101929. doi: 10.1016/j.cpr.2020.101929. Epub 2020 Oct 17. — View Citation

Gaudiano BA, Herbert JD. Acute treatment of inpatients with psychotic symptoms using Acceptance and Commitment Therapy: pilot results. Behav Res Ther. 2006 Mar;44(3):415-37. doi: 10.1016/j.brat.2005.02.007. Erratum In: Behav Res Ther. 2020 Jan;124:103534. — View Citation

Hayes SC, Hofmann SG, Ciarrochi J. A process-based approach to psychological diagnosis and treatment:The conceptual and treatment utility of an extended evolutionary meta model. Clin Psychol Rev. 2020 Dec;82:101908. doi: 10.1016/j.cpr.2020.101908. Epub 2020 Sep 7. — View Citation

Moritz S, Woodward TS. Metacognitive training in schizophrenia: from basic research to knowledge translation and intervention. Curr Opin Psychiatry. 2007 Nov;20(6):619-25. doi: 10.1097/YCO.0b013e3282f0b8ed. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Eligibility rate	proportion of those eligible to participate as a percentage of those screened	assessed from study start in May 2021 until study completition in May 2022, up to 1 year
Primary	Consent rate	proportion of those who signed the informed consent as a percentage of those who where approached to participate	assessed from study start in May 2021 until study completition in May 2022, up to 1 year
Primary	Trial entry rate	proportion of those who consented and completed baseline measures	assessed from study start in May 2021 until study completition in May 2022, up to 1 year
Primary	Completion rate	proportion of assessments completed at each time point including screening, baseline, intervention and final meeting and reasons for missing data; subjective patient feedback on frequency, duration, delivery, method and content of the assesments	assessed from study start in May 2021 until study completition in May 2022, up to 1 year
Primary	Missing data rate	proportion of missing data for each time point including screening, baseline, intervention and final meeting	assessed from study start in May 2021 until study completition in May 2022, up to 1 year
Primary	Patient engagement	frequency of unattended sessions per patient as well as the reason for non-attendance	assessed from study start in May 2021 until study completition in May 2022, up to 1 year
Primary	Drop out rate	proportion of patients who entered the trial, attended at least one therapy session after baseline but decided to drop out as well as reasons for the drop out	assessed from study start in May 2021 until study completition in May 2022, up to 1 year
Primary	Adverse events	number and nature of adverse events	assessed from study start in May 2021 until study completition in May 2022, up to 1 year
Primary	Acceptability of Module I	self-rating on subjective effectiveness and acceptability of Module I (one session Psychoeducation). The questionnaire will be designed in a manner similar to session feedback forms developed by Moritz and Woodward (2007) including likert-scaled items on satisfaction, effectiveness, usefulness, applicability and transparency of the aim as well as open-ended feedback	after completion of Module I in week 1
Primary	Acceptability of Module II	self-rating on subjective effectiveness and acceptability of Module II (four sessions Metacognition). The questionnaire will be designed in a manner similar to session feedback forms developed by Moritz and Woodward (2007) including likert-scaled items on satisfaction, effectiveness, usefulness, applicability and transparency of the aim as well as open-ended feedback	after completion of Module II in week 3
Primary	Acceptability of Module III	self-rating on subjective effectiveness and acceptability of Module III (four sessions Cognitive Defusion). The questionnaire will be designed in a manner similar to session feedback forms developed by Moritz and Woodward (2007) including likert-scaled items on satisfaction, effectiveness, usefulness, applicability and transparency of the aim as well as open-ended feedback	after completion of Module III in week 5
Primary	Semi-structured interviews	conducted with one randomly selected patient out of every therapy cycle after completion; selected patients will be asked in detail about feasibility and perceived efficacy of the group program	after completing Module III in week 5
Secondary	Psychopathological in general and positive and negative psychotic symptoms (PANSS)	assessed with the semi-structured clinical interview Positive and Negative Syndrome Scale (PANSS), the internationally most widely used measure of psychotic symptomatology. The scale ranges from a minimum of 30 (no symptomatology) up to a maximum of 126 (severe symptomatology)	before session 1 in week 1 and after completing the therapy in week 5
Secondary	Psychopathological in general and positive and negative psychotic symptoms (BPRS)	assessed with the semi-structured clinical interview Brief Psychiatric rating scale (BPRS), next to PANSS the internationally second most used measure of psychotic symptomatology. The scale ranges from a minimum of 18 (no symptomatology) up to 210 (severe symptomatology)	before session 1 in week 1 and after completing the therapy in week 5
Secondary	Positive symptoms (hallucinatiosn and delusions) and their severity, intensity and frequency (PSYRATS)	measured with the clinical interview Psychotic Symptom Rating Scale (PSYRATS). The subscale auditory hallucinations ranges from a minimum of 0 (no distress) up to a maximum of 44 (high distress), the subscale delusions from a minimum of 0 (no distress) up to a maximum of 24 (high distress)	before session 1 in week 1 and after completing the therapy in week 5
Secondary	Patient's improvement (CGI)	will be gathered with the Clinical Global Impression Scale (CGI). The Severity scale ranges from a minimum of 1 (not at all ill) up to a maximum of 7 (among the most ill patients) and the Improvement scale from a minimum of 1 (very much improved) up to a maximum of 7 (very much worse)	The patient's supervising MD will rate CGI's severity scale for each patient in week 1 and week 5, and the improvement scale only after week 5
Secondary	Social functioning (WHODAS)	social functioning will be self-administered by patients through the World Health Organisation Disability Assessment Schedule (WHODAS).	in week 1 and week 5
Secondary	Therapy processes of metacognition (BCIS)	Beck's Cognitive Insight Scale (BCIS) will be filled in from patients to measure cognitive insight. Scores on the subscale Self-reflectiveness range from a minimum of 0 (high self-reflectiveness) to a maximum of 36 (high self-reflectiveness), scores on the subscale Self-Certainty range from a minimum of 0 (high self-certainty) to a maximum of 24 (low self-certainty)	before starting Module II in week 2 and after completing Module II in week 3
Secondary	Degree of Cognitive fusion (CFQ)	The Cognitive Fusion Questionnaire (CFQ) will be surveyed from patients to measure the degree of cognitive fusion. The scale ranges from a minimum of 7 (low cognitive fusion) up to a maximum of 49 (high cognitive fusion)	before starting Module III in week 4 and after completing Module II in week 5